| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
18,552 |
16,689 |
$1.41M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
9,797 |
8,237 |
$524K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
3,045 |
2,844 |
$237K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,662 |
1,371 |
$169K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,332 |
1,159 |
$154K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,369 |
1,252 |
$132K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
834 |
731 |
$130K |
| 80053 |
Comprehensive metabolic panel |
7,638 |
6,189 |
$92K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,311 |
1,079 |
$81K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
3,160 |
2,511 |
$44K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
491 |
438 |
$43K |
| A9270 |
Non-covered item or service |
4,377 |
1,374 |
$38K |
| 87070 |
|
1,867 |
1,723 |
$31K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
596 |
540 |
$27K |
| 71046 |
Radiologic examination, chest; 2 views |
2,207 |
1,971 |
$26K |
| 81001 |
|
4,774 |
4,066 |
$20K |
| 85027 |
|
11,164 |
8,748 |
$19K |
| 87400 |
|
3,111 |
2,891 |
$19K |
| 71045 |
Radiologic examination, chest; single view |
3,648 |
3,095 |
$18K |
| G0378 |
Hospital observation service, per hour |
511 |
327 |
$13K |
| 81003 |
|
2,374 |
2,082 |
$12K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
2,225 |
1,843 |
$10K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
4,476 |
3,599 |
$9K |
| 82044 |
|
1,071 |
888 |
$9K |
| 73630 |
|
318 |
293 |
$8K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
1,101 |
690 |
$8K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
366 |
290 |
$8K |
| 84484 |
|
2,739 |
1,919 |
$7K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
4,202 |
3,324 |
$6K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
43 |
25 |
$6K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,868 |
4,856 |
$6K |
| 81025 |
|
3,019 |
2,728 |
$6K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
1,981 |
1,838 |
$5K |
| 73564 |
|
122 |
115 |
$5K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
337 |
286 |
$5K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
118 |
85 |
$5K |
| 83735 |
|
2,126 |
1,661 |
$4K |
| 73130 |
|
157 |
147 |
$3K |
| 74018 |
|
43 |
40 |
$3K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
21 |
16 |
$3K |
| 85610 |
|
1,923 |
1,539 |
$3K |
| 87430 |
|
1,665 |
1,596 |
$3K |
| 87077 |
|
570 |
472 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
964 |
782 |
$3K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
1,991 |
1,379 |
$3K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,010 |
659 |
$2K |
| 84702 |
|
302 |
239 |
$2K |
| 85730 |
|
885 |
712 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
88 |
76 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
314 |
196 |
$2K |
| 83690 |
|
3,035 |
2,541 |
$2K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
59 |
38 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
2,504 |
1,941 |
$2K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
70 |
24 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
142 |
108 |
$2K |
| J7050 |
Infusion, normal saline solution, 250 cc |
1,631 |
1,327 |
$1K |
| 73610 |
|
114 |
96 |
$1K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,665 |
2,052 |
$1K |
| 87280 |
|
241 |
229 |
$1K |
| 86900 |
|
384 |
310 |
$1K |
| 87040 |
|
838 |
601 |
$1K |
| 86901 |
|
385 |
310 |
$1K |
| 87186 |
|
441 |
359 |
$1K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
2,568 |
1,825 |
$1K |
| 73030 |
|
55 |
48 |
$1K |
| J3490 |
Unclassified drugs |
199 |
136 |
$1K |
| 82945 |
|
1,071 |
891 |
$940.10 |
| 73110 |
|
62 |
51 |
$930.35 |
| 80306 |
|
435 |
375 |
$753.19 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,192 |
1,001 |
$729.00 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
111 |
106 |
$586.38 |
| 84703 |
|
757 |
662 |
$573.40 |
| 87088 |
|
108 |
97 |
$390.86 |
| 12001 |
|
15 |
15 |
$349.68 |
| 96376 |
|
322 |
198 |
$211.89 |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
42 |
36 |
$166.34 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
111 |
106 |
$153.96 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
217 |
197 |
$98.37 |
| 86850 |
|
96 |
65 |
$87.09 |
| G1003 |
Clinical decision support mechanism medicalis, as defined by the medicare appropriate use criteria program |
56 |
46 |
$70.97 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
794 |
729 |
$70.08 |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
104 |
44 |
$59.78 |
| 83880 |
|
161 |
141 |
$56.02 |
| 85379 |
|
172 |
160 |
$52.34 |
| J2704 |
Injection, propofol, 10 mg |
14 |
12 |
$25.40 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
364 |
311 |
$10.54 |
| 84443 |
Thyroid stimulating hormone (TSH) |
117 |
101 |
$7.68 |
| 83605 |
|
648 |
532 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
261 |
230 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
151 |
112 |
$0.00 |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
20 |
12 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
1,060 |
805 |
$0.00 |
| S0028 |
Injection, famotidine, 20 mg |
32 |
28 |
$0.00 |
| 93976 |
|
14 |
13 |
$0.00 |
| 85007 |
|
13 |
13 |
$0.00 |